Abiopharma

🔍 LEYKUM ELIZABETH (Director)

Company: Valaris Ltd (VAL)

Report Date: 2026-06-10

Detailed Transactions and Holdings:

• Acquired 6,978 shares of Common Shares (Direct)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,811.00 | transaction_form_type: 4
• Sold 2,792 shares of Common Shares at $88.98 per share (Direct)
  Date: 2026-06-10 | Code: D | equity_swap_involved: 0 | shares_owned_after: 43,019.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,978 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 2,849 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,849.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: Represents the portion of restricted stock units that were cash settled in accordance with the terms of the reporting person's equity award agreement.
• F2: Each restricted stock unit represents the right to receive one Valaris common share, the cash value thereof, or a combination of shares and cash, in accordance with the grant agreements and at the election of the reporting person.
• F3: Each restricted stock unit represents the right to receive one Valaris common share, the cash value thereof, or a combination of shares and cash, in accordance with the grant agreements and at the election of the reporting person. Consists of 2,849 restricted stock units, representing the recipient's annual equity retainer, which will vest in full on the earlier of the first anniversary of the date of grant or the next annual meeting of the Company's shareholders.